Cargando…
Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
PURPOSE: This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. MATERIALS AND METHODS: From a total of 37 patients, 19 with International Federation of Gynecology...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394869/ https://www.ncbi.nlm.nih.gov/pubmed/22802747 http://dx.doi.org/10.4143/crt.2012.44.2.97 |
_version_ | 1782237906216157184 |
---|---|
author | Kim, Hee Seung Kim, Mi-Kyung Kim, Hak Jae Han, Seung-Su Kim, Jae Weon |
author_facet | Kim, Hee Seung Kim, Mi-Kyung Kim, Hak Jae Han, Seung-Su Kim, Jae Weon |
author_sort | Kim, Hee Seung |
collection | PubMed |
description | PURPOSE: This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. MATERIALS AND METHODS: From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m(2)) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m(2)) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. RESULTS: The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. CONCLUSION: Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer. |
format | Online Article Text |
id | pubmed-3394869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-33948692012-07-16 Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer Kim, Hee Seung Kim, Mi-Kyung Kim, Hak Jae Han, Seung-Su Kim, Jae Weon Cancer Res Treat Original Article PURPOSE: This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. MATERIALS AND METHODS: From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m(2)) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m(2)) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. RESULTS: The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. CONCLUSION: Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer. Korean Cancer Association 2012-06 2012-06-30 /pmc/articles/PMC3394869/ /pubmed/22802747 http://dx.doi.org/10.4143/crt.2012.44.2.97 Text en Copyright © 2012 by the Korean Cancer Association http://creativecommons.org/licenses/by-nc/3.0 This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Hee Seung Kim, Mi-Kyung Kim, Hak Jae Han, Seung-Su Kim, Jae Weon Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer |
title | Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer |
title_full | Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer |
title_fullStr | Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer |
title_full_unstemmed | Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer |
title_short | Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer |
title_sort | phase ii study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394869/ https://www.ncbi.nlm.nih.gov/pubmed/22802747 http://dx.doi.org/10.4143/crt.2012.44.2.97 |
work_keys_str_mv | AT kimheeseung phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer AT kimmikyung phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer AT kimhakjae phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer AT hanseungsu phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer AT kimjaeweon phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer |